A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Conditions
B-cell Lymphoma · Non-Hodgkin Lymphoma · B-cell Malignancy · Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) · Follicular Lymphoma · Mantle Cell Lymphoma · Marginal Zone Lymphoma · Large B-cell Lymphoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Kansas, Westwood, Kansas, United States
Washington University, St Louis, Missouri, United States
SCRI, San Antonio, Texas, United States
University of Utah, Salt Lake City, Utah, United States
Royal Prince Alfred, Camperdown, New South Wales, Australia
Alfred Health, Melbourne, Victoria, Australia
Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
Study leads
Melanie Allen, M.Sc.
Study Director
CRISPR Therapeutics